Related Experiment Video
Updated: Mar 9, 2026

Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
ROCK2/rasHa co-operation induces malignant conversion via p53 loss, elevated NF-κB and tenascin C-associated
S F Masre1,2, N Rath3,4, M F Olson3,4
1Section of Dermatology and Molecular Carcinogenesis, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, Glasgow University, Glasgow, UK.
Abstract:
To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-activated ROCK2 (K14.ROCKer) were crossed with mice expressing epidermal-activated rasHa (HK1.ras1205). At 8 weeks, 4HT-treated K14.ROCKer/HK1.ras1205 cohorts exhibited papillomas similar to HK1.ras1205 controls; however, K14.ROCKer/HK1.ras1205 histotypes comprised a mixed papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, increased proliferation and novel NF-κB expression. By 12 weeks, K14.ROCKer/HK1.ras1205 wdSCCs exhibited increased NF-κB and novel tenascin C, indicative of elevated rigidity; yet despite continued ROCK2 activities/p-Mypt1 inactivation, progression to SCC required loss of compensatory p21 expression. K14.ROCKer/HK1.ras1205 papillomatogenesis also required a wound promotion stimulus, confirmed by breeding K14.ROCKer into promotion-insensitive HK1.ras1276 mice, suggesting a permissive K14.ROCKer/HK1.ras1205 papilloma context (wound-promoted/NF-κB+/p53-/p21+) preceded K14.ROCKer-mediated (p-Mypt1/tenascin C/rigidity) malignant conversion. Malignancy depended on ROCKer/p-Mypt1 expression, as cessation of 4HT treatment induced disorganized tissue architecture and p21-associated differentiation in wdSCCs; yet tenascin C retention in connective tissue extracellular matrix suggests the rigidity laid down for conversion persists. Novel papilloma outgrowths appeared expressing intense, basal layer p21 that confined endogenous ROCK2/p-Mypt1/NF-κB to supra-basal layers, and was paralleled by restored basal layer p53. In later SCCs, 4HT cessation became irrelevant as endogenous ROCK2 expression increased, driving progression via p21 loss, elevated NF-κB expression and tenascin C-associated rigidity, with p-Mypt1 inactivation/actinomyosin-mediated contractility to facilitate invasion. However, p21-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 and rasHa/ROCK2/NF-κB signalling in skin carcinogenesis. Collectively, these data show that ROCK2 activation induces malignancy in rasHa-initiated/promoted papillomas in the context of p53 loss and novel NF-κB expression, whereas increased tissue rigidity and cell motility/contractility help mediate tumour progression.
Insights
ROCK2 activation promotes skin carcinogenesis in mice by inducing squamous cell carcinoma. This process involves p53 loss, NF-κB expression, and increased tissue rigidity, with p21 acting as a key inhibitor.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Rho-associated coiled-coil containing kinase 2 (ROCK2) plays a role in cell motility and tissue rigidity.
- Ras homologue (RasHa) activation is a known driver of skin carcinogenesis.
- Understanding the interplay between ROCK2, RasHa, and tumor suppressors is crucial for cancer research.
Purpose of the Study:
- To investigate the role of ROCK2 activation in skin carcinogenesis initiated by RasHa.
- To elucidate the molecular mechanisms by which ROCK2 contributes to tumor progression and malignancy.
- To identify potential therapeutic targets by understanding the signaling pathways involved.
Main Methods:
- Utilized genetically engineered mouse models expressing inducible ROCK2 (K14.ROCKer) and epidermal-activated RasHa (HK1.ras1205).
- Administered 4-hydroxytamoxifen (4HT) to activate ROCK2 and observed tumor development over 8 and 12 weeks.
- Analyzed histopathology, proliferation markers, p53, NF-κB, p21, tenascin C, and p-Mypt1 expression in tumor tissues.
Main Results:
- ROCK2 activation in RasHa-initiated papillomas led to well-differentiated squamous cell carcinoma (wdSCC) with p53 loss and increased NF-κB.
- Tumor progression to SCC required p21 loss, and was associated with increased tenascin C and tissue rigidity.
- Cessation of ROCK2 activation induced p21-associated differentiation, while sustained activation in later SCCs drove invasion via p21 loss and increased contractility.
Conclusions:
- ROCK2 activation is a critical driver of malignancy in RasHa-initiated and promoted skin tumors, particularly in the context of p53 loss and NF-κB activation.
- Increased tissue rigidity and altered cell contractility mediated by ROCK2 are key factors in tumor progression and invasion.
- A novel antagonism between p21 and RasHa/ROCK2/NF-κB signaling was identified, highlighting p21's role in inhibiting early-stage malignant progression.
Related Concept Videos
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

